<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134564">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01999179</url>
  </required_header>
  <id_info>
    <org_study_id>PRO21429</org_study_id>
    <nct_id>NCT01999179</nct_id>
  </id_info>
  <brief_title>Post-thrombotic Syndrome &amp; Predictors of Recurrence in Catheter-related Thrombosis</brief_title>
  <official_title>Pilot Study of Post-thrombotic Syndrome &amp; Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood Center of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the pilot study is to determine if a multicenter prospective cohort study of
      cancer patients with blood clots associated with catheters is feasible. Cancer patients with
      catheter-related thrombosis treated with one month of anticoagulation will be evaluated for
      for post-thrombotic syndrome. Laboratory biomarkers will be evaluated as predictors of
      recurrent thrombosis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recruitment of 56 patients in 1 year and 80% completion of post-thrombotic syndrome assessments by enrolled patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Obtaining 80% of samples from enrolled patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of post-thrombotic syndrome</measure>
    <time_frame>6 months after catheter removal</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of recurrent thrombosis</measure>
    <time_frame>6 months after catheter removal</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of major and clinically relevant non-major bleeding</measure>
    <time_frame>6 months after catheter removal</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Venous Thrombosis</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>1 month low-molecular-weight heparin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cancer patients treated with 1 month of low-molecular-weight heparin after catheter removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin, Low-Molecular-Weight</intervention_name>
    <description>Cancer patients treated with low-molecular-weight heparin for 1 month after catheter removal</description>
    <arm_group_label>1 month low-molecular-weight heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Upper extremity venous thrombosis associated with an indwelling catheter documented
             by ultrasound, CT or venography

          -  Current hematologic or solid tumor malignancy undergoing chemotherapy, surgery,
             radiation or hormonal therapy for malignancy.

          -  &gt;18 years of age

          -  Platelet count &gt;50,000

          -  Creatinine clearance &gt;30 ml/min

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Underlying medical condition or chemotherapy requiring long-term anticoagulation

          -  Known underlying higher risk thrombophilias including antiphospholipid antibody
             syndrome, antithrombin, protein C or protein S deficiencies, or homozygosity or
             compound heterozygosity for prothrombin G20210A or Factor V R506Q mutations.

          -  Inability to remove venous catheter

          -  Anticipated replacement of central venous catheter within 3 months

          -  Major bleeding or clinically relevant non-major bleeding in the preceding 60 days

          -  Participation in another clinical trial that requires anticoagulation

          -  Use of anticoagulant other than low-molecular weight heparin

          -  Treatment with thrombolysis

          -  Catheter removal &gt;1 month prior to enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Baumann Kreuziger, MD, MS</last_name>
    <phone>414-937-6826</phone>
    <email>lisa.baumannkreuziger@bcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mark Reding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Baumann Kreuziger, MD, MS</last_name>
      <phone>414-937-6826</phone>
      <email>lisa.baumannkreuziger@bcw.edu</email>
    </contact>
    <investigator>
      <last_name>Baumann Kreuziger Lisa, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parameswaran Hari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>November 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Lisa Baumann Kreuziger</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>catheter related thrombosis</keyword>
  <keyword>upper extremity deep venous thrombosis</keyword>
  <keyword>central venous catheters</keyword>
  <keyword>cancer</keyword>
  <keyword>Catheters</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
